Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TK216 in Chinese patients with relapsed or refractory Ewing sarcoma
CTR20211685Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TK216 in Ewing sarcoma, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jul 2021; status: completed.
02
Drugs
TK216
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on CTR20211685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211685.